Jpmorgan Chase & CO Castle Biosciences Inc Transaction History

Jpmorgan Chase & CO

$1.1 Trillion
Q1 2024

A detailed history of Jpmorgan Chase & CO transactions in Castle Biosciences Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 76,143 shares of CSTL stock, worth $1.66 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

76,143

Previous 50,366 51.18%

Holding current value

$1.66 Million

Previous $1.09 Million 55.25%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$18.06 - $25.3 $465,532 - $652,158	25,777 Added 51.18%	76,143 $1.69 Million
Q4 2023 Feb 12, 2024	SELL	$12.19 - $22.43 $28,000 - $51,521	-2,297 Reduced 4.36%	50,366 $1.09 Million
Q3 2023 Nov 14, 2023	BUY	$13.28 - $20.3 $15,471 - $23,649	1,165 Added 2.26%	52,663 $889,000
Q2 2023 Aug 11, 2023	BUY	$11.66 - $26.0 $83,602 - $186,420	7,170 Added 16.17%	51,498 $706,000
Q1 2023 May 18, 2023	BUY	$19.47 - $28.49 $602,187 - $881,167	30,929 Added 230.83%	44,328 $1.01 Million

Q1 2023 May 11, 2023	SELL	$19.47 - $28.49 $428,320 - $626,751	-21,999 Reduced 62.15%	13,399 $304,000
Q4 2022 Feb 13, 2023	BUY	$18.08 - $30.0 $44,277 - $73,470	2,449 Added 7.43%	35,398 $833,000
Q3 2022 Nov 14, 2022	BUY	$22.51 - $34.32 $63,613 - $96,988	2,826 Added 9.38%	32,949 $860,000
Q2 2022 Aug 11, 2022	BUY	$16.0 - $45.99 $92,784 - $266,696	5,799 Added 23.84%	30,123 $661,000
Q1 2022 May 11, 2022	BUY	$33.17 - $46.98 $25,010 - $35,422	754 Added 3.2%	24,324 $1.09 Million
Q4 2021 Feb 10, 2022	BUY	$39.06 - $67.58 $57,691 - $99,815	1,477 Added 6.69%	23,570 $1.01 Million
Q3 2021 Nov 12, 2021	BUY	$60.13 - $77.6 $1.33 Million - $1.71 Million	22,093 New	22,093 $1.47 Million

Others Institutions Holding CSTL

# of Institutions

162

Shares Held

25.3M

Call Options Held

82.2K

Put Options Held

150K

View Full List

About CASTLE BIOSCIENCES INC

Ticker CSTL
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 26,297,000
Market Cap $572M
Description
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...

More about CSTL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Castle Biosciences Inc Transaction History